Ignite Creation Date:
2025-12-24 @ 2:14 PM
Ignite Modification Date:
2026-01-23 @ 8:51 AM
Study NCT ID:
NCT03385395
Status:
WITHDRAWN
Last Update Posted:
2018-04-10
First Post:
2017-12-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency
Sponsor:
Octapharma
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-07
Start Date Type:
ESTIMATED
Primary Completion Date:
2019-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2019-12
Completion Date Type:
ESTIMATED
First Submit Date:
2017-12-01
First Submit QC Date:
None
Study First Post Date:
2017-12-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-04-06
Last Update Post Date:
2018-04-10
Last Update Post Date Type:
ACTUAL